Tests ADCE-T02, a targeted drug, in advanced solid tumours
Tests ADCE-T02 in adults with advanced solid tumours, including pancreatic and head and neck cancers.
Plain-language title generated from the registry record
Registry title: ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
Key facts
- Where
- Bedford Park, Frankston, Macquarie Park, Malvern, Melbourne, Nedlands, and Randwick, AustraliaSee the 7 sites
- Phase
- Phase 1
Where in Australia
- Southern Oncology Clinical Research UnitBedford Park, AustraliaTaking people
- Peninsula and South Eastern Haematology and Oncology Group (PSEHOG)Frankston, AustraliaTaking people
- Macquarie University HospitalMacquarie Park, AustraliaTaking people
- Cabrini HospitalMalvern, AustraliaTaking people
- Peter MacCallum Cancer CentreMelbourne, AustraliaTaking people
- Linear Clinical ResearchNedlands, AustraliaTaking people
- Scientia Clinical ResearchRandwick, AustraliaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Adcendo ApS
- Trial code
- NCT06597721
- Record updated
- 9 September 2026
- Original description
Adcendo ApS is conducting a phase 1 study of an investigational drug called ADCE-T02 (previously known as AMT-754), a tissue factor targeted antibody-drug conjugate which may be used in the future as a possible treatment for advanced solid tumors.Read full original descriptionShow less
First-in-Human, Phase 1 Study of ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors
Adcendo ApS is conducting a phase 1 study of an investigational drug called ADCE-T02 (previously known as AMT-754), a tissue factor targeted antibody-drug conjugate which may be used in the future as a possible treatment for advanced solid tumors.
The main purpose of the study is to determine the Maximum Tolerated Dose (MTD), the recommended dose and the safety and tolerability of ADCE-T02 when given as a single therapy over a range of different dose levels.
The expansion phase is now open for enrollment in indications including HNSCC and PDAC.
Inclusion: Patients must have pathologically confirmed unresectable advanced solid tumor; Patients who have undergone at least one systemic therapy and have progressive disease; Patients must have at least one measurable lesion as per RECIST version 1.1; Eastern Cooperative Oncology Group (ECOG) performance status of 0-1; Life expectancy ≥ 3 months; Patients must have adequate organ function as indicated by laboratory values; Women of childbearing potential (WCBP), defined as sexually mature women who have not undergone surgical sterilization or who have not been naturally postmenopausal for at least 12 consecutive months must agree to use two effective contraceptive methods while on study treatment and for at least 7 months after the last dose of ADCE T02; Male patients must agree to use condoms, even if they have had a successful vasectomy, while on study treatment and for at least 4 months after the last dose of ADCE T02.
Exclusion: Prior treatment with any agent targeting Tissue Factor or any ADC with a topoisomerase 1 payload; Persistent toxicities from previous systemic anti-neoplastic treatments; Active ocular surface disease or a history of cicatricial conjunctivitis or inflammatory conditions that predispose to cicatrizing conjunctivitis, mucus pemphigoid or penetrating ocular transplants; Known past or current coagulation defects leading to an increased risk of bleeding; Significant cardiac disease; recent myocardial infarction, acute coronary syndromes, congestive heart failure, uncontrolled hypertension, uncontrolled cardiac arrhythmias; History of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids, or current ILD/pneumonitis, or suspected ILD/pneumonitis; Prior second malignancy except for:; Well treated basal cell carcinoma or squamous cell carcinoma of the skin; Low-risk prostate cancer with a Gleason score < 7 and a PSA level < 10 ng/mL; Any cancer or in situ cancer the patient has been disease-free for ≥ 2 years; Central nervous system (CNS) metastasis.